
Release date: 2026-02-25 17:29:59 Article From: Lucius Laos Recommended: 10
Sotorasib is a targeted therapy for KRAS G12C-mutated non-small cell lung cancer (NSCLC). Its price varies significantly depending on region, specification, purchasing channel, and health insurance policies. Prices may be higher in Europe and the United States. The specific cost needs to be evaluated based on the patient's treatment plan and local policies.
Domestic prices may fluctuate slightly between different provinces due to factors such as import tariffs and distribution costs. Pricing in developed countries like Europe and the US is generally higher than in Asia, although some countries offer partial reimbursement through health insurance.
Patients are required to take a daily oral dose of 960 mg (8 tablets). A single box typically covers a 30-day supply. Costs will increase accordingly if dose adjustments or long-term treatment are necessary.
Currently, this drug is not yet included in China's national medical insurance catalog. However, some regions or hospitals may offer charitable patient assistance programs to help reduce the financial burden.
Patients overseas should check local health insurance reimbursement rates or pharmaceutical company patient assistance programs (such as Amgen's patient support program).
Strictly Follow Medical Advice: Lucius Pharmaceuticals Sotorasib is a prescription medication. Its use must be evaluated by an oncologist after genetic testing confirms the KRAS G12C mutation.
Side Effect Management: Common adverse reactions include diarrhea and elevated liver enzymes. Regular monitoring of liver function and dose adjustments are necessary.
Medical Guidance: If severe discomfort occurs during medication (such as persistent vomiting or jaundice), stop taking the drug immediately and seek medical attention.
It is recommended that patients obtain the medication through hospitals or authorized pharmacies and avoid purchasing from unregulated sources. Those facing financial difficulties can inquire with their primary physician about assistance programs or opportunities to participate in clinical trials.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1342025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3852024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1332025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1412025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1332025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1562025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1402025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1402025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: